AVITA Medical, Inc. (RCEL) Discusses Business Progress, Operational Changes and Sequential Revenue Growth Transcript
AVITA Medical, Inc. (RCEL) Discusses Business Progress, Operational Changes and Sequential Revenue Growth Transcript
Avita Medical Q1 Earnings Call Highlights
Avita Medical NASDAQ: RCEL reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook as management said reimbursement conditions for its RECELL product are normalizing and demand patterns are becoming more consistent.
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?
Avita Medical (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts Believe Avita Medical (RCEL) Could Rally 29.87%: Here's is How to Trade
The consensus price target hints at a 29.9% upside potential for Avita Medical (RCEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AVITA Medical, Inc. (RCEL) Discusses Financial Performance, Sales Strategy, and Reimbursement Progress Transcript
AVITA Medical, Inc. (RCEL) Discusses Financial Performance, Sales Strategy, and Reimbursement Progress Transcript
AVITA Medical, Inc. (RCEL) Q4 2025 Earnings Call Transcript
AVITA Medical, Inc. (RCEL) Q4 2025 Earnings Call Transcript
Avita Medical: Set Up For A Turnaround
Avita Medical has an innovative automated wound-healing regenerative system called RECELL Go that uses a small patient skin sample to seed an 80x larger wound. This high-margin product works faster than the standard of care and provides superior results, incentivizing burn and trauma centers to adopt the device. Complementary new products, PermeaDerm and Cohealyx, vertically integrate the wound bend and provide lucrative synergies.
AVITA Medical, Inc. (RCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AVITA Medical, Inc. (RCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AVITA Medical, Inc. (RCEL) Discusses Advanced Wound Care Solutions and Data-Driven Approaches in Clinical Healing Transcript
AVITA Medical, Inc. ( RCEL ) Discusses Advanced Wound Care Solutions and Data-Driven Approaches in Clinical Healing November 12, 2025 5:00 PM EST Company Participants Ben Atkins - Vice President of Investor Relations & Corporate Communications Cary Vance - Independent Non-Executive Chairman & Interim CEO Presentation Ben Atkins Vice President of Investor Relations & Corporate Communications [Audio Gap] Cary Vance Independent Non-Executive Chairman & Interim CEO [Audio Gap] In each case, we believe our products are best from a clinical perspective, but also that they speed up the time to graft, the time to heal, which is extremely important for the patient and potential complications, but also important for the hospital that is trying to -- that is striving to make economic progress themselves. And so PermeaDerm is a biosynthetic dressing that protects the wound, that stabilizes the wound.
AVITA Medical, Inc. (RCEL) Q3 2025 Earnings Call Transcript
AVITA Medical, Inc. ( RCEL ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Ben Atkins - Vice President of Investor Relations & Corporate Communications Cary Vance - Independent Non-Executive Chairman & Interim CEO David OToole - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald & Co., Research Division Joshua Jennings - TD Cowen, Research Division Chris Kallos - MST Financial Services Pty Limited, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the AVITA Medical, Inc. Third Quarter 2025 Earnings Conference Call.
